[{"indications": "Indications\u00a0dermatophytoses and Malassezia folliculitis either resistant to fluconazole, terbinafine, or itraconazole or in patients intolerant of these antifungals; chronic\r\nmucocutaneous, cutaneous, and oropharyngeal candidiasis either resistant to fluconazole or itraconazole or in\r\npatients intolerant of these antifungals", "name": "KETOCONAZOLE ", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.2 Antifungal drugs", "5.2.2 Imidazole antifungals", "KETOCONAZOLE"], "cautions": "Cautions\u00a0predisposition to adrenocortical insufficiency; interactions: Appendix 1 (antifungals, imidazole)Hepatotoxicity\u00a0Potentially life-threatening hepatotoxicity\r\nreported very rarely; risk of hepatotoxicity greater\r\nif given for longer than 10 days. Monitor\r\nliver function before treatment, then on weeks 2 and 4 of treatment,\r\nthen every month. Avoid or use with caution\r\nif abnormal liver function tests (avoid in active liver disease) or if history of hepatotoxicity\r\nwith other drugsCounselling\u00a0Patients should be told\r\nhow to recognise signs of liver disorder and advised to seek prompt\r\nmedical attention if symptoms such as anorexia, nausea, vomiting,\r\nfatigue, abdominal pain, jaundice, or dark urine develop", "side-effects": "Side-effects\u00a0nausea, vomiting, abdominal pain; pruritus; less commonly diarrhoea, headache, dizziness, drowsiness,\r\nand rash; also reported fatal liver damage (see Hepatotoxicity above),\r\ndyspepsia, raised intracranial pressure, paraesthesia, adrenocortical\r\ninsufficiency, erectile dysfunction, menstrual disorders, azoospermia\r\n(with high doses), gynaecomastia, thrombocytopenia, photophobia, photosensitivity,\r\nand alopecia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3984.htm", "doses": ["200\u00a0mg once daily, increased if response inadequate to\r\n400\u00a0mg once daily; continued until symptoms have cleared and cultures\r\nnegative, but see Cautions (max. duration of treatment 4 weeks for Malassezia infection); child body-weight 15\u201330\u00a0kg, 100\u00a0mg once daily; body-weight over 30\u00a0kg,\r\nadult dose"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless potential benefit\r\noutweighs risk (teratogenicity in animal studies)"}, {"indications": "Indications\u00a0fungal skin infections; systemic or resistant fungal\r\ninfections (section 5.2.2); vulval candidiasis (section 7.2.2)", "name": "KETOCONAZOLE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.10 Anti-infective skin preparations", "13.10.2 Antifungal preparations"], "cautions": "Cautions\u00a0\n(From 13.10.2 Antifungal preparations: British National Formulary)\nCautions\u00a0Contact with eyes and mucous membranes should be avoided.", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/6161.htm", "doses": ["Tinea pedis, apply twice daily; other fungal infections,\r\napply 1\u20132 times daily"]}]